Dr Brian Kelly, Dr Frank D’Arcy, Dr Mark Quinlan, Dr Farhad Kheradmand, Dr Nadeem Nusrat and Mr Syed Jaffry examine the diagnosis and treatment of BPH and LUTS.
Time to open up about problems down below
July 15, 2011 By Leave a Comment
Benign prostatic hyperplasia affects one quarter of men over the age of 40, but the first step to getting treatment is talking about the problem to a GP, writes Aoife McCann.
Benign prostatic hyperplasia — nature’s classic design fault
March 25, 2011 By Leave a Comment
Dr Andrew Rynne looks at the common problem of BPH and gives his views on differing surgical and pharmacological treatments for the condition.
Profal
November 1, 2009 By
Company: Actavis Ireland Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Finasteride 5mg Description: Blue, round, biconvex film-coated tablet marked F5. Presentation: 28, €20.66. Indications: Treatment and control of benign prostatic hyperplasia (BPH) in patients with an enlarged prostate to cause regression of the enlarged prostate, improve urinary flow and improve the symptoms associated [...]
Carsem XL
September 1, 2009 By
Company: Teva Pharmaceuticals Ireland. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Doxazosin (as mesilate), 4mg. Description: White, round biconvex film-coated prolonged-release tablets with DL bossing on one side. Presentation: 28, €12.82. Indications: Essential hypertension: Not appropriate for first-line treatment, may be used as a monotherapy in patients who have failed to respond to or [...]
Finasteride Ranbaxy
April 1, 2009 By
Company: Ranbaxy UK. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Finasteride 5mg. Description: White, round, biconvex, film-coated tablet, diameter 7 mm, embossed F and 5 on one side. Presentation: 28, €17.88. Indications: Treatment and control of benign prostatic hyperplasia (BPH) to cause regression of the enlarged prostate, improve urinary flow and improve the symptoms [...]
Fintex
January 5, 2009 By
Company: Helsinn Birex Therapeutics Ltd. Legal category: Prescription. GMS pending. Sport permitted. Active ingredient: Finasteride 5mg. Description: Blue, 7mm, round biconvex, film-coated tablets marked F5 on one side. Presentation: 28, €17.00. Indications: Treatment and control of benign prostatic hyperplasia (BPH) and prevention of urologic events to reduce the risk of acute urinary retention, reduce the [...]
Finocar
December 1, 2008 By
Company: Pinewood Healthcare. Legal category: Prescription. GMS. Sport prohibited. Active ingredient: Finasteride 5mg. Description: Light blue spherical biconvex film-coated tablet. Presentation: 28, €22.76. Indications: Treatment and control of benign prostatic hyperplasia (BPH) in patients with an enlarged prostate (prostate volume above 40ml) to cause regression of the enlarged prostate, improve urinary flow and improve the [...]
Tevax
February 1, 2008 By
Company: TEVA Pharmaceuticals Ireland. Legal category: Prescription. GMS. Sport Permitted. Active ingredient: Alfuzosin hydrochloride10mg. Description: White, round, bevelled-edges, prolonged releasetablet. Presentation: 30, €18.78. Indications: Moderate to severe functional symptoms of benignprostatic hyperplasia (BPH). Pharmacology: Alfuzosin is an orally acting quinazolin derivative,which selectively blocks post-synaptic alpha-1-receptors and thus relaxessmooth muscle and improves urinary flow. Dosage: Adult: [...]
Loading ...
